Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study

Summary Background Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congeni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric pulmonology 2015-10, Vol.50 (10), p.1025-1032
Hauptverfasser:	Ozyurt, Abdullah, Narin, Nazmi, Baykan, Ali, Argun, Mustafa, Pamukcu, Ozge, Zararsiz, Gokmen, Sunkak, Suleyman, Uzum, Kazim
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Case-Control Studies clinical trials congenital heart disease Female Heart Defects, Congenital - epidemiology hospitalization Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Intensive Care Units lower respiratory tract infections Male Palivizumab - therapeutic use palivizumab prophylaxis Respiratory Syncytial Virus Infections - prevention & control Respiratory Tract Infections - epidemiology Respiratory Tract Infections - prevention & control Retrospective Studies risk factors RSV Turkey - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background Palivizumab prophylaxis for RSV has been consistently reported to reduce the risk of hospital admissions related to RSV infection in children with symptomatic cardiac disease. This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey. Methods A total of 91 infants with CHD who received palivizumab prophylaxis and 96 infants with CHD without prophylaxis (0–12 months:52; 12–24 months:44) were included in this single‐center retrospective case control study. Data on patient characteristics, household environment, and LRTIs were evaluated. Results In patients without prophylaxis, the rate of overall lower respiratory tract infections (LRTIs) (P
ISSN:	8755-6863 1099-0496
DOI:	10.1002/ppul.23102